Phase 2 N=110 A Study of Acne Treatment in Children Ages 9 to 11
Acne Vulgaris
Primary: Change From Baseline in Total Non-inflammatory Lesion Count — -19.9; -9.7 Lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet® Ointment — -5.15 Scores on a scale
Phase 2 N=157 A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
HIV Infection · HIV · Acquired Immunodeficiency Syndrome
Primary: Proportion of Patients With at Least 1 Treatment-emergent Grade 1-4 Central Nervous System or Psychiatric Adverse Event — 16.5; 46.2 percentage of patients — p=<0.001
Phase 2 N=55 MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
Paranoid Schizophrenia
Primary: Mean Change From Baseline at 4 Weeks of Treatment in Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery. — 0.4; 0.5 Composite…
Phase 2 N=435 A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 287; 273 Days — p=0.3883
Phase 2 N=36 Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline at Day 28 in 24-hour Urinary Glucose Excretion — 35.729; 47.085; -0.965 grams
Phase 2 N=133 Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
Prostate Cancer
Primary: Probability of Testosterone at Castration Level (≤0.5 ng/mL) From Day 28 Through Day 364 — 89.0; 93.3 percentage of participants
Phase 2 N=95 Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Prostate Cancer
Primary: Number of Participants With a Response — 12; 13 participants
Phase 2 N=785 Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery
Open-heart Surgery · Cardiopulmonary Bypass
Primary: Number of Participants Who Had Significant Hypotension as Defined in the Protocol as Need for Norepinephrine Dose >0.1mcq/kg/Min in the First 72 Hours Postoperatively…
Phase 2 N=180 A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
Schizophrenia
Primary: Change From Baseline to the End of the Double-blind Treatment in the BPRS (Brief Psychiatric Rating Scale) Total Score — -8.9; -4.2 units on a scale — p=<0.05
Phase 2 N=22 Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Adverse Events — 16; 5 Participants
Phase 2 N=54 Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006
Phase 2 N=26 Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation
Acute Wounds
Primary: Number of Patients Who Experienced 50% or Greater Wound Healing — 13; 7; 4 Participants
Phase 2 N=19 Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days) — 12 Subjects
Phase 2 N=102 A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 4.4; 5.5 Months — p=0.0097